Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
NPJ Breast Cancer
.
2023 Aug 18;9(1):69.
doi: 10.1038/s41523-023-00575-6.
Authors
Lorna Hopcroft
1
,
Eleanor M Wigmore
2
,
Stuart C Williamson
1
,
Susana Ros
1
,
Cath Eberlein
1
,
Jennifer I Moss
1
,
Jelena Urosevic
1
,
Larissa S Carnevalli
1
,
Sara Talbot
1
,
Lauren Bradshaw
1
,
Catherine Blaker
1
,
Sreeharsha Gunda
3
,
Venetia Owenson
4
,
Scott Hoffmann
4
,
Daniel Sutton
4
,
Stewart Jones
4
,
Richard J A Goodwin
4
,
Brandon S Willis
5
,
Claire Rooney
6
,
Elza DeBruin
6
,
Simon T Barry
7
Affiliations
1
Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
2
Early Data Science, Oncology Data Science, AstraZeneca, Cambridge, UK.
3
Information Technology, AstraZeneca, Chennai, Tamil Nadu, India.
4
Imaging Sciences, AstraZeneca, Cambridge, UK.
5
Bioscience Early Oncology, AstraZeneca, Boston, MA, USA.
6
Translational Medicine, AstraZeneca, Cambridge, UK.
7
Bioscience Early Oncology, AstraZeneca, Cambridge, UK. Simon.T.Barry@astrazeneca.com.
PMID:
37596288
PMCID:
PMC10439172
DOI:
10.1038/s41523-023-00575-6
No abstract available
Publication types
Published Erratum